Outlook Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Aug 14, 2024 and accepted by EDGAR at Aug 14, 2024, 20:15 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2024-04-01 to 2024-06-30 | $11.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-10-01 to 2024-06-30 | $29.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-04-01 to 2024-06-30 | −$19.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-10-01 to 2024-06-30 | −$48.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 9 months2023-10-01 to 2024-06-30 | $3.2m | us-gaap:InterestExpense |
| Income tax | 9 months2023-10-01 to 2024-06-30 | $2.8k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-04-01 to 2024-06-30 | $44.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-10-01 to 2024-06-30 | −$81.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-04-01 to 2024-06-30 | −$0.89 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-10-01 to 2024-06-30 | −$4.82 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-04-01 to 2024-06-30 | $1.91 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-10-01 to 2024-06-30 | −$4.82 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-04-01 to 2024-06-30 | 25,476,438 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-10-01 to 2024-06-30 | 16,822,774 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-10-01 to 2024-06-30 | −$51.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2024-06-30 | $32.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-06-30 | $45.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $47.1m | us-gaap:Assets |
| Current liabilities | At period end2024-06-30 | $42.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-06-30 | $130.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-06-30 | −$83.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-24-012234. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.